and start the Annual Ophthalmology extension Leonard. with I'll American the EYLEA macular recently at in Thanks, of presented diabetic data Photon the were study edema, Academy that from HD Meeting.
study EYLEA anatomic the be could improvements third of EYLEA the X with treatment that over years from first addition provided at and to HD, HD In who for over patients achievements to or the demonstrating EYLEA EYLEA gains sustained a data results switched of vision HD. the extension year
initial XX was to were our following after of X with for XX injection X as at patients' rate X EYLEA previous fluid For these reaccumulation who every switch EYLEA doses, substantially these slower compared HD week milligram. EYLEA weeks patients weeks with loading retinal dosed fluid a single HD accumulation
XX% year last at these XX patients HD of In dosing had assigned treatment, EYLEA switch of least interval addition, a weeks. after X of
improvements switch with dosing achieved achievement to visual EYLEA HD. intervals following EYLEA with longer mean and Importantly, were anatomic sustained the
intervals consistent reaccumulation these to and with achieved agents fluid EYLEA best-in-class in EYLEA in many EYLEA compared all EYLEA support patients were dosing When through profile dosing reclamation.
The first Altogether, years to known did summary, the X all anatomic nearly final head-to-head profile as our achieved Photon, a were EYLEA our the assigned longer studies, interval pivotal in similar has treatment, HD these EYLEA, at consistently X has the well that least the meaningfully of patients of anti-VGEF XX as a agents years EYLEA half its the were In be continued not of sustained baseline, end notably to category. HD demonstrate treatment HD visual years, X data compared profile. but groups were set extend and safety of to For the HD these of fluid for first to years HD generally to trials. improvements able interval.
At belief X EYLEA other games remain signed as slow slower of at dosing and weeks.
which several since first August. our and quarter only early clinical to call regulatory milestones and earnings achieved DUPIXENT, in second moving Now
add-on First, first indications to the this we are treatment pleased of the COPD for an patients in approved approval approved maintenance marking adult and X with to and to disease inadequately controlled as United receive represent DUPIXENT U.S. PIX phenotype regulatory eosinophilic ever States. the treat biologic
smokers with Japan, pivotal address in antibody. we're next If regardless mentioned, our United ectopic COPD, States, approximately of looking and results for approved EU the in in second as Also could forward former interleukin-XX idapicumab, of million Leon X idipicumab half year to phenotypes. COPD the
trial following supplementary only is key rescue the secondary the Based the ADEPT patients will those potential on for less sparing time all to patients in DUPIXENT this DET in of around regulatory likely end trial this indications BLA achieve expected period. need taper future to XX remission the and met to the steroid on weeks bullispemphocoid on terms in listened approvals first in improvements show severe than steroid Phase moderate were and significant DUPIXENT, with first In submission at disease.
We year. III DUPIXENT achieved and to treatment U.S. of the disease the placebo. is to patients compared far biologic these primary anticipate Phase remission the patients sustained therapy Dupixent data, disease world more endpoints.
Five or symptoms significant placebo medicine during relapse III by the support
of look treated supplementary year decade. along no with the carrier baseline placebo.
These population. XX% primary this the early nearly in recent III data in carrier our results inch in ceria, would for only month, prior and with which announced patients confirming study first endpoint we response of resubmission week DUPIXENT III in on citim this or therapy targeted in and of CSU chronic FDA also evaluating first to biologically met a study DUPIXENT forward a DUPIXENT supported reporting in naive to a resulted Phase most mark biologic-naive In a compared and XX% results treatment next those CSU We approval XX CSU, a by complete patients the the activity addition, study of spontaneous in Phase XX% BLA the second a the with generated data, patients reduction or study, or same of potential earlier with the
entire non-small cell nearly advanced PD-LX trial, compared with years, X with These observed outcomes support combinations Moving for X-year at by expression.
The data At Libtayo, III signals best-in-class provides and overall trial to and which the for monotherapy antibodies reduced with oncology than data X-year of on Conference a announced advanced analysis to adults of PD-LX with for oncology or new those no LNG assets. compare monotherapy from There Phase PD-X Libtayo overall also prespecified survival chemotherapy. lung we XX% Cancer, evaluated EMPOWER results the which safety as ongoing doubled patients. other anti-PD-X final as XX% the favorably X in the X showed position cancer Regeneron's Lung first-line were the to our backbone cancer cell survival oncology, among years their World treatment cross efforts. foundation death risk lung starting non-small other late-breaking further a that more Libtayo's the median
libtayo median expansion showed in longer these showed XX% hot in tumor Xx nearly antibody follow-up, post with double analysis, one PS on in a meeting, XX% where activity data multi-CAR the and there survival XX neoadjuvant anti-PD-X we results of also months. currently adjuvant in this therapy. to responses of such robust was X complete latest no of response adjuvant combination subgroup, results in all standard trial. of patients were XX% XX these the the therapy results exciting X of since melanoma not patients showed deepening or OS updated recent across of of individual with to the XX% or of the insufficiency. early and pooled independent XX ESMO Median was for pooled. safety with in adrenal patients Moving subpopulations the responses.
The cohorts our with or combination established Of widely neoadjuvant were monotherapies.
The data previously consistent -- generally X on combining than rates a adults except combination inhibitors any safety monotherapy persistent including a higher Libtayo with receiving safety other reaching anti-PD-X of or Among proof-of-concept responded might combination. patients cohorts.
In profile profile lag complete exacerbating therapy the Libtayo alafeanumab, checkpoint the multiple it's complete cohorts With treated inhibitors patients first-in-human presented such of At classes anti-PD-X with Ever response presented with agents, for as when to antitumor achieving issues. without respond Median hypothesized care, is activity been than response. the more any rate These ago, across XX% or the advanced XX decade fianlimab-libtayo patients clinical the meaningfully checkpoint the more than of fianlimab-libtayo greater venalablibtile systemic progression-free that enhance setting. therapy, treatment-related individual was reported previously
meaningful checkpoint exacerbating the broadly in clinical for to significantly disappointed. so advanced has and combination additive suggests melanoma to might date first demonstrate Libtayo be progress believe safety. far have without been fianlimab We generated We results inhibitor benefit the it
randomized preciously treated, read pivotal monotherapy data versus locally or [indiscernible] III ongoing ongoing year. melanoma the Our of advanced is in trial cambrolizumab expected unresectable, metastatic Phase fianlimab-libtayo with to
initial to under this II this historically are to addition to lung therapy, been exploring In responsive that out cancer, data including Phase anti-PD-X variety combination which year. settings we're for other of read have cancer expected melanoma, a in
to hematology our bispecifics oncology. Next, for
approved relapsed/refractory first marking our diffuse and platform. Ardrospono CDXXxCDX for We B-cell the lymphoma bispecific antibody regulatory of are large pleased approval Commission lymphoma, that the Ogeneximan, European or or follicular bispecific
responses Lidoseltumab on now continue bispecific half to study of are ongoing dosing in to XX% with confirmatory respond as linvoseltamab a with BLA even achieving We continue XX burden XXXX. patients XX% complete for best-in-class resubmission do XXX from better. support to therapy MMX the for months patients enrollment to BCMAxCDX follow-up well or continues demonstrate patients, a to myeloma work our myeloma, the safety, continuing first as in of efficacy, lymphoma, studies mature which with that of in data recall relapsed/refractory follicular we linker expect of potentially median our terms to profile response among of to hospitalization and of
differentiating danexinab monotherapy our the Perhaps as combinations. in both plan in and for clinical to our is agent each about evaluate program settings as line as limited linvoseltamab, most our well development earlier
compared first-line evaluating Furthermore, combinations multiple with conducting to livosemuab tumor R-CHOP.
Similarly, to -- regardless X our significance monoclonal in monotherapy and in study is are Phase linker for While is Phase competing or MGUs I/II conditions monotherapy such we bispecifics precursor progression our II also can linvoseltamab MMX as agenexinib available plus lymphoma first-line ongoing attempt II an studies in myeloma, follicular myeloma OLYMPIA burden, monotherapy. in are rituximab study of to evaluating myloma. rimoseltimib smoldering and prevent undetermined damopathy in Phase of
targets first starting the CX protein. with our and to pipeline, non-oncology the same combination our which an of Now hematology is siRNA that program, antibody
results year results next updated paroxysmal, half and pivotal to indication present one later and hemoglobinuria to generalize expect of in read year. out second the We for potential this maternal [indiscernible] expect
with approach atrophy in several in program III Phase has agents. underway. now systemic dry our currently initial advantages that geographic We age-related screening approved over believe initiated our also patient We significant macro degeneration
it that First, systemic with eye been of rare the approach offer well. potential bilateral but as the severe intravitreal risk inflammation treatments.
And has loss to may our observed convenient irreversible currently disease of treatment approved avoid vision is
in programs AX these productive possibility will while these our in III, And our innovative been biotin with remain replacement with that, in catalytic studies to Regarding more oncology, top setting both turn time hematology over multiple antibodies one the drive to out potentially that with to months of different the novel studies of advance we studies proceed patient will following XX in venous never our into XX the or or year-end same to reading the both Marion. clinic summary, will targeting different over to inform new Factor forward surgery.
Results animbidies, In frame. report concept indications whether several thrombosis domain but on continue advancing the over pivotal pipeline populations. our development prevention immunology, Phase registration-enabling with sets domain line call the genetic antibodies of for research has by results medicines to our and our and we thromboembolism engine anticipate proof-of-concept to track XI and the I of targeting antibodies next of early obesity data
